# Heterocyclization of 5-(Arylmethylidene)pyrimidine-2,4,6(1*H*,3*H*,5*H*)-triones with Arenecarbaldehyde Oximes in the Presence of *N*-Bromosuccinimide and Triethylamine

A. G. Tyrkov<sup>*a*</sup>\* and E. A. Yurtaeva<sup>*b*</sup>\*\*

<sup>a</sup> Astrakhan State University, Astrakhan, Russia \*e-mail: tyrkov@rambler.ru

<sup>b</sup> Pyatigorsk Medical and Pharmaceutical Institute (Branch), Volgograd State Medical University, Pyatigorsk, Russia \*\*e-mail: huitre\_88@mail.ru

Received January 9, 2019; revised March 10, 2019; accepted March 15, 2019

**Abstract**—5-(Arylmethylidene)pyrimidine-2,4,6(1*H*,3*H*,5*H*)-triones reacted with substituted benzaldehyde oximes in the presence of *N*-bromosuccinimide and triethylamine to give 1,4-diaryl-2-oxa-3,7,9-triazaspiro-[4.5]dec-3-ene-6,8,10-triones and 3,4-diaryl-1,2,5-oxadiazole *N*-oxides.

**Keywords:** 5-(arylmethylidene)pyrimidine-2,4,6(1*H*,3*H*,5*H*)-triones, arenecarbaldehyde oximes, 1,3-dipolar cycloaddition, *N*-bromosuccinimide, triethylamine, 1,4-diaryl-2-oxa-3,7,9-triazaspiro[4.5]dec-3-ene-6,8,10-triones, 3,4-diaryl-1,2,5-oxadiazole *N*-oxides.

DOI: 10.1134/S1070428019070108

Published data on chemical transformations of benzonitrile oxides generated by dehydrohalogenation of benzohydroximoyl chlorides with triethylamine are limited to 1,3-dipolar cycloadditions to conjugated or unconjugated nitroethenes, which lead to the formation of 3,5-substituted dihydroisoxazoles [1, 2]. Reactions of nitrile oxides with trinitroacetonitrile and ethyl chloro(cyano)nitroacetate afforded 5-nitromethyl-1,2,4-oxadiazole derivatives [3–5]. Heterocyclizations of 5-(arylmethylidene)pyrimidine-2,4,6(1*H*,3*H*,5*H*)triones with nitrile oxides generated *in situ* from aromatic aldehyde oximes by the action of *N*-bromosuccinimide (NBS) and triethylamine were not studied previously.

In continuation of our studies of the synthetic potential of reactions of nitrile oxides with various dipolarophiles, in this work we examined reactions of substituted benzonitrile oxides with 5-(arylmethylidene)barbituric acids 1a-1d. The reactions of 1a-1d with oximes 2a-2c were carried out in the presence of NBS and triethylamine in DMF at  $0-5^{\circ}$ C. As a result, we isolated a series of previously unknown 1,4-diaryl-2-oxa-3,7,9-triazaspiro[4.5]dec-3-ene-6,8,10-triones 3a-31 in 35-38% yield. In addition, from the reaction mixtures we isolated products of spontaneous

dimerization of intermediate nitrile oxides, 3,4-diaryl-1,2,5-oxadiazole *N*-oxides 4a-4c in 52–55% yield (Scheme 1).

Presumably, oximes 2a-2c react with NBS and triethylamine to produce nitrile oxides A, and 1,3-dipolar cycloaddition of the latter to dipolarophiles 1a-1dgives 1,4-diaryl-2-oxa-3,7,9-triazaspiro[4.5]dec-3-ene-6,8,10-triones 3a-3l. The possibility of generation of nitrile oxides by the action of NBS on aromatic aldehyde oximes in the presence of triethylamine was demonstrated previously [6]. The low yields of 3a-3land the formation of nitrile oxide dimerization products 4a-4c may be rationalized by the low reactivity of barbituric acids 1a-1d in comparison to trinitroacetonitrile oxides undergo dimerization independently of the presence of 1a-1d in the reaction mixture.

Compounds 3a-3l are stable colorless or colored high-melting solids soluble in ethanol. The structure of 3a-3l was determined on the basis of their IR, <sup>1</sup>H and <sup>13</sup>C NMR, and mass spectra and elemental analyses. The IR spectra of 3a-3l showed no C=C stretching band at 1625 cm<sup>-1</sup>, which was typical of initial pyrimidine-2,4,6-triones 1a-1d [7]. The <sup>1</sup>H and <sup>13</sup>C NMR spectral parameters of 3a-3l were consistent with the Scheme 1.



1,  $Ar^{1} = Ph(a)$ ,  $4-MeOC_{6}H_{4}(b)$ ,  $4-Me_{2}NC_{6}H_{4}(c)$ ,  $4-MeC_{6}H_{4}(d)$ ; 2,  $Ar^{2} = Ph(a)$ ,  $4-MeOC_{6}H_{4}(b)$ ,  $4-Me_{2}NC_{6}H_{4}(c)$ ; 3,  $Ar^{1} = Ar^{2} = Ph(a)$ ,  $Ar^{1} = Ph$ ,  $Ar^{2} = 4-MeOC_{6}H_{4}(b)$ ,  $4-Me_{2}NC_{6}H_{4}(c)$ ;  $Ar^{1} = 4-MeOC_{6}H_{4}$ ,  $Ar^{2} = Ph(d)$ ,  $4-MeOC_{6}H_{4}(e)$ ,  $4-Me_{2}NC_{6}H_{4}(f)$ ;  $Ar^{1} = 4-Me_{2}NC_{6}H_{4}$ ,  $Ar^{2} = Ph(d)$ ,  $4-MeOC_{6}H_{4}(e)$ ,  $4-Me_{2}NC_{6}H_{4}(f)$ ;  $Ar^{1} = 4-MeC_{6}H_{4}$ ,  $Ar^{2} = Ph(d)$ ,  $4-MeOC_{6}H_{4}(e)$ ,  $4-Me_{2}NC_{6}H_{4}(f)$ ;  $Ar^{1} = 4-MeC_{6}H_{4}$ ,  $Ar^{2} = Ph(d)$ ,  $4-MeOC_{6}H_{4}(e)$ ,  $4-Me_{2}NC_{6}H_{4}(f)$ ;  $4, Ar^{2} = Ph(d)$ ,  $4-MeOC_{6}H_{4}(e)$ ,  $4-Me_{2}NC_{6}H_{4}(f)$ ;  $4, Ar^{2} = Ph(d)$ ,  $4-MeOC_{6}H_{4}(e)$ ,  $4-Me_{2}NC_{6}H_{4}(f)$ ;  $4, Ar^{2} = Ph(d)$ ,  $4-MeOC_{6}H_{4}(e)$ ,  $4-Me_{2}NC_{6}H_{4}(f)$ ;  $4, Ar^{2} = Ph(d)$ ,  $4-MeOC_{6}H_{4}(f)$ ,  $4-Me_{2}NC_{6}H_{4}(f)$ ;  $4, Ar^{2} = Ph(d)$ ,  $4-MeOC_{6}H_{4}(f)$ ,  $4-MeOC_{6}H_{4}(f)$ ;  $4, Ar^{2} = Ph(d)$ ,  $4-MeOC_{6}H_{4}(f)$ ,  $4-MeOC_{6}H_{4}(f)$ ;  $4, Ar^{2} = Ph(d)$ ,  $4-MeOC_{6}H_{4}(f)$ .

proposed structure and with the spectra of model compounds of the dihydroisoxazole series [8]. For instance, in the <sup>1</sup>H NMR spectra of **3a–31** we observed a signal at  $\delta$  5.30–5.38 ppm due to proton in the isoxazole ring, which was absent in the spectra of initial compounds. The <sup>13</sup>C NMR spectra displayed a new signal at  $\delta_{\rm C}$  164.2–164.8 ppm due to the C=N carbon atom in the same ring. The molecular ion and  $[M - H]^+$  ion peaks in the mass spectra of **3a–3l** had low intensity, but ion peaks corresponding to dissociative ionization via retro-1,3-dipolar cycloaddition at the C-O and C-C bonds of the isoxazole ring were distinguished. Apart from the above noted ions, there was a set of ion peaks to which several formulas could be assigned; therefore, more detailed interpretation of the mass spectra was difficult.

Thus, the reaction of 5-(arylmethylidene)pyrimidine-2,4,6(1H,3H,5H)-triones **1a**-1**d** with substituted benzaldehyde oximes **2a**-2**c** in the presence of NBS and triethylamine provides the possibility of incorporating a dihydroisoxazole ring into the base part of molecule **1a**-1**d** in a one-pot fashion. The obtained compounds are interesting as potential biologically active substances, in particular as antibacterial agents or imidazoline receptor agonists [9, 10].

### **EXPERIMENTAL**

The IR spectra in the range 4000–400 cm<sup>-1</sup> were recorded on an InfraLUM FT-02 spectrometer from samples pelletized with KBr. The <sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded on a Bruker Avence II 300 SF instrument at 500 and 125 MHz, respectively, using DMSO- $d_6$  as solvent and hexamethyldisiloxane as internal standard. The mass spectra (electron impact, 70 eV) were obtained on a Finnigan SSQ-7000 mass spectrometer with direct sample admission into the ion source; vaporization temperature 500–550°C. The progress of reactions and the purity of the isolated compounds were monitored by ascending thin-layer chromatography on Silufol UV-254 plates using acetone–hexane (2:3) as eluent; spots were visualized by treatment with iodine vapor [11]. The elemental compositions were determined using a Euro Vector EA-3000 automated CHNS analyzer. The melting (decomposition) points were measured with an OptiMelt melting point apparatus.

5-(Arylmethylidene)pyrimidine-2,4,6-(1H,3H,5H)triones **1a–1d** [12], aromatic aldehyde oximes **2a–2c** [13], and NBS [14] were synthesized according to previously described procedures; triethylamine of chemically pure grade was commercial product (Aldrich).

1,4-Diaryl-2-oxa-3,7,9-triazaspiro[4.5]dec-3-ene-6.8.10-triones 3a-3l (general procedure). A mixture of 6 mmol of N-bromosuccinimide and 6 mmol of aldehyde oxime 2a-2c in 30 mL of anhydrous DMF was vigorously stirred for 30 min at 0°C, a solution of 6.5 mmol of triethylamine in 5 mL of DMF was added, and 5 mmol of compound 1a-1d was then added under vigorous stirring. The mixture was stirred for 30 min at 0-5°C and kept for 24 h at 20-25°C, and the precipitate was filtered off and washed with 10 mL of DMF. The solvent was evaporated under reduced pressure, and the residue was subjected to chromatography in a glass column charged with activated silica (100-400 µm). Compounds **3a–31** were eluted with ethanol, compounds 4a and 4b, with benzene, and compound 4c, with chloroform.

**1,4-Diphenyl-2-oxa-3,7,9-triazaspiro**[**4.5**]dec-**3**ene-**6,8,10-trione (3a).** Yield 0.586 g (35%), colorless crystals, mp 235–239°C (decomp.). IR spectrum, v, cm<sup>-1</sup>: 3355 (NH), 1770, 1750 (C=O). <sup>1</sup>H NMR spectrum,  $\delta$ , ppm: 5.38 s (1H, CH), 7.35–7.58 m (10H, H<sub>arom</sub>), 11.42 br.s (1H, NH), 11.47 br.s (1H, NH). <sup>13</sup>C NMR spectrum,  $\delta_{\rm C}$ , ppm: 62.3 (C<sup>5</sup>), 69.5 (C<sup>1</sup>), 128.1–142.5 (C<sub>arom</sub>), 152.2 (C<sup>6</sup>), 161.3 (C<sup>10</sup>), 162.5 (C<sup>8</sup>), 164.7 (C<sup>4</sup>). Mass spectrum, *m/z* (*I*<sub>rel</sub>, %): 335 (10) [*M*]<sup>+-</sup>, 334 (4) [*M* – 1]<sup>+</sup>, 216 (100), 119 (20.4). Found, %: C 64.32; H 3.76; N 12.36. C<sub>18</sub>H<sub>13</sub>N<sub>3</sub>O<sub>4</sub>. Calculated, %: C 64.47; H 3.91; N 12.53. *M* 335.31.

**4-(4-Methoxyphenyl)-1-phenyl-2-oxa-3,7,9-triazaspiro[4.5]dec-3-ene-6,8,10-trione (3b).** Yield 0.676 g (37%), pale yellow crystals, mp 245–248°C (decomp.). IR spectrum, v, cm<sup>-1</sup>: 3355 (NH), 1770, 1750 (C=O). <sup>1</sup>H NMR spectrum,  $\delta$ , ppm: 3.82 s (3H, CH<sub>3</sub>O), 5.37 s (1H, CH), 6.90–7.52 m (9H, H<sub>arom</sub>), 11.43 br.s (1H, NH), 11.48 br.s (1H, NH). <sup>13</sup>C NMR spectrum,  $\delta_{\rm C}$ , ppm: 55.6 (CH<sub>3</sub>O), 62.4 (C<sup>5</sup>), 68.4 (C<sup>1</sup>), 114.4–158.5 (C<sub>arom</sub>), 161.5 (C<sup>6</sup>), 161.9 (C<sup>10</sup>), 162.7 (C<sup>8</sup>), 164.2 (C<sup>4</sup>). Mass spectrum, *m/z* (*I*<sub>rel</sub>, %): 365 (8) [*M*]<sup>+-</sup>, 364 (5) [*M* – 1]<sup>+</sup>, 216 (100), 149 (25.2). Found, %: C 62.31; H 3.97; N 11.32. C<sub>19</sub>H<sub>15</sub>N<sub>3</sub>O<sub>5</sub>. Calculated, %: C 62.46; H 4.14; N 11.50. *M* 365.34.

**4-(4-Dimethylaminophenyl)-1-phenyl-2-oxa-3,7,9-triazaspiro[4.5]dec-3-ene-6,8,10-trione (3c).** Yield 0.719 g (38%), red crystals, mp 310–314°C (decomp.). IR spectrum, v, cm<sup>-1</sup>: 3355 (NH), 1770, 1750 (C=O). <sup>1</sup>H NMR spectrum,  $\delta$ , ppm: 2.43 s (6H, CH<sub>3</sub>N), 5.37 s (1H, CH), 6.95–7.55 m (9H, H<sub>arom</sub>), 11.43 br.s (1H, NH), 11.48 br.s (1H, NH). <sup>13</sup>C NMR spectrum,  $\delta_{\rm C}$ , ppm: 40.7 (CH<sub>3</sub>N), 62.5 (C<sup>5</sup>), 68.3 (C<sup>1</sup>), 112.6–154.4 (C<sub>arom</sub>), 161.4 (C<sup>6</sup>), 161.6 (C<sup>10</sup>), 162.5 (C<sup>8</sup>), 164.6 (C<sup>4</sup>). Mass spectrum, *m/z* (*I*<sub>rel</sub>, %): 378 (9) [*M*]<sup>+-</sup>, 377 (6) [*M* – 1]<sup>+</sup>, 216 (100), 162 (26.5). Found, %: C 63.32; H 4.67; N 14.62. C<sub>20</sub>H<sub>18</sub>N<sub>4</sub>O<sub>4</sub>. Calculated, %: C 63.48; H 4.79; N 14.81. *M* 378.38.

**1-(4-Methoxyphenyl)-4-phenyl-2-oxa-3,7,9-triazaspiro[4.5]dec-3-ene-6,8,10-trione (3d).** Yield 0.657 g (36%), pale yellow crystals, mp 215–219°C (decomp.). IR spectrum, v, cm<sup>-1</sup>: 3355 (NH), 1770, 1750 (C=O). <sup>1</sup>H NMR spectrum, δ, ppm: 3.81 s (3H, CH<sub>3</sub>O), 5.36s (1H, CH), 6.90–7.55 m (9H, H<sub>arom</sub>), 11.43 br.s (1H, NH), 11.48 br.s (1H, NH). <sup>13</sup>C NMR spectrum,  $\delta_{\rm C}$ , ppm: 55.8 (CH<sub>3</sub>O), 61.7 (C<sup>5</sup>), 68.2 (C<sup>1</sup>), 114.5–160.2 (C<sub>arom</sub>), 161.3 (C<sup>6</sup>), 161.7 (C<sup>10</sup>), 162.2 (C<sup>8</sup>), 164.5 (C<sup>4</sup>). Mass spectrum, *m/z* (*I*<sub>rel</sub>, %): 365 (11) [*M*]<sup>+-</sup>, 364 (6) [*M* – 1]<sup>+</sup>, 246 (100), 119 (20.6). Found, %: C 62.28; H 3.96; N 11.33. C<sub>19</sub>H<sub>15</sub>N<sub>3</sub>O<sub>5</sub>. Calculated, %: C 62.46; H 4.14; N 11.50. *M* 365.34.

**1,4-Bis(4-methoxyphenyl)-2-oxa-3,7,9-triazaspiro[4.5]dec-3-ene-6,8,10-trione (3e).** Yield 0.751 g (38%), pale yellow crystals, mp 282–286°C (decomp.). IR spectrum, v, cm<sup>-1</sup>: 3355 (NH), 1770, 1750 (C=O). <sup>1</sup>H NMR spectrum,  $\delta$ , ppm: 3.80 s (3H, CH<sub>3</sub>O), 3.81 s (3H, CH<sub>3</sub>O), 5.37 s (1H, CH), 6.90–7.52 m (8H, H<sub>arom</sub>), 11.43 br.s (1H, NH), 11.46 br.s (1H, NH). <sup>13</sup>C NMR spectrum,  $\delta_{\rm C}$ , ppm: 55.3 (CH<sub>3</sub>O), 55.5 (CH<sub>3</sub>O), 61.6 (C<sup>5</sup>), 61.8 (C<sup>1</sup>), 113.8–158.3 (C<sub>arom</sub>), 161.4 (C<sup>6</sup>), 161.8 (C<sup>10</sup>), 162.3 (C<sup>8</sup>), 164.1 (C<sup>4</sup>). Mass spectrum, *m/z* (*I*<sub>rel</sub>, %): 395 (8) [*M*]<sup>++</sup>, 394 (5) [*M* – 1]<sup>+</sup>, 246 (100), 149 (26.5). Found, %: C 60.58; H 4.17; N 10.48. C<sub>20</sub>H<sub>17</sub>N<sub>3</sub>O<sub>6</sub>. Calculated, %: C 60.76; H 4.33; N 10.63. *M* 395.37.

**4-(4-Dimethylaminophenyl)-1-(4-methoxyphenyl)-2-oxa-3,7,9-triazaspiro[4.5]dec-3-ene-6,8,10-trione (3f).** Yield 0.755 g (37%), pale yellow crystals, mp 305–309°C (decomp.). IR spectrum, v, cm<sup>-1</sup>: 3355 (NH), 1770, 1750 (C=O). <sup>1</sup>H NMR spectrum, δ, ppm: 2.42 s (6H, CH<sub>3</sub>N), 3.80 s (3H, CH<sub>3</sub>O), 5.34 s (1H, CH), 6.95–7.55 m (8H, H<sub>arom</sub>), 11.42 br.s (1H, NH), 11.48 br.s (1H, NH). <sup>13</sup>C NMR spectrum,  $\delta_{\rm C}$ , ppm: 40.5 (CH<sub>3</sub>N), 55.4 (CH<sub>3</sub>O), 62.6 (C<sup>5</sup>), 68.1 (C<sup>1</sup>), 112.8–155.2 (C<sub>arom</sub>), 161.5 (C<sup>6</sup>), 161.8 (C<sup>10</sup>), 162.8 (C<sup>8</sup>), 164.5 (C<sup>4</sup>). Mass spectrum, *m/z* (*I*<sub>rel</sub>, %): 408 (10) [*M*]<sup>++</sup>, 407 (5), [*M* – 1]<sup>+</sup>, 246 (100), 162 (25.3). Found, %: C 61.60; H 4.77; N 13.54. C<sub>21</sub>H<sub>20</sub>N<sub>4</sub>O<sub>5</sub>. Calculated, %: C 61.76; H 4.94; N 13.72. *M* 408.41.

**1-(4-Dimethylaminophenyl)-4-phenyl-2-oxa-3,7,9-triazaspiro[4.5]dec-3-ene-6,8,10-trione (3g).** Yield 0.663 g (35%), pink crystals, mp 280–285°C (decomp.). IR spectrum, v, cm<sup>-1</sup>: 3355 (NH), 1770, 1750 (C=O). <sup>1</sup>H NMR spectrum, δ, ppm: 2.41 s (6H, CH<sub>3</sub>N), 5.37 s (1H, CH), 6.95–7.58 m (9H, H<sub>arom</sub>), 11.42 br.s (1H, NH), 11.48 br.s (1H, NH). <sup>13</sup>C NMR spectrum,  $\delta_{\rm C}$ , ppm: 40.7 (CH<sub>3</sub>N), 62.7 (C<sup>5</sup>), 68.3 (C<sup>1</sup>), 112.5–154.7 (C<sub>arom</sub>), 161.5 (C<sup>6</sup>), 161.7 (C<sup>10</sup>), 162.6 (C<sup>8</sup>), 164.6 (C<sup>4</sup>). Mass spectrum, *m/z* (*I*<sub>rel</sub>, %): 378 (12) [*M*]<sup>+-</sup>, 377 (8), [*M* – 1]<sup>+</sup>, 259 (100), 119 (20.5). Found, %: C 63.32; H 4.61; N 14.62. C<sub>20</sub>H<sub>18</sub>N<sub>4</sub>O<sub>4</sub>. Calculated, %: C 63.48; H 4.79; N 14.81. *M* 378.13.

1-(4-Dimethylaminophenyl)-4-(4-methoxyphenyl)-2-oxa-3,7,9-triazaspiro[4.5]dec-3-ene-6,8,10-trione (3h). Yield 0.779 g (38%), pink crystals, mp 320–325°C (decomp.). IR spectrum, v, cm<sup>-1</sup>: 3355 (NH), 1770, 1750 (C=O). <sup>1</sup>H NMR spectrum,  $\delta$ , ppm: 2.40 s (6H, CH<sub>3</sub>N), 3.80 s (3H, CH<sub>3</sub>O), 5.30 s (1H, CH), 6.90–7.54 m (8H, H<sub>arom</sub>), 11.42 br.s (1H, NH), 11.48 br.s (1H, NH). <sup>13</sup>C NMR spectrum,  $\delta_{C}$ , ppm: 40.4 (CH<sub>3</sub>N), 55.3 (CH<sub>3</sub>O), 62.5 (C<sup>5</sup>), 68.1 (C<sup>1</sup>), 112.7–155.4 (C<sub>arom</sub>), 161.4 (C<sup>6</sup>), 161.7 (C<sup>10</sup>), 162.8 (C<sup>8</sup>), 164.5 (C<sup>4</sup>). Mass spectrum, m/z ( $I_{rel}$ , %): 408 (10) [M]<sup>+-</sup>, 407 (5), [M – 1]<sup>+</sup>, 259 (100), 149 (25.2). Found, %: C 61.58; H 4.81; N 13.54. C<sub>21</sub>H<sub>20</sub>N<sub>4</sub>O<sub>5</sub>. Calculated, %: C 61.76; H 4.94; N 13.72. M 408.41. **1,4-Bis(4-dimethylaminophenyl)-2-oxa-3,7,9-triazaspiro[4.5]dec-3-ene-6,8,10-trione (3i).** Yield 0.782 g (37%), red crystals, mp 272–277°C (decomp.). IR spectrum, v, cm<sup>-1</sup>: 3355 (NH), 1770, 1750 (C=O). <sup>1</sup>H NMR spectrum,  $\delta$ , ppm: 2.40 s (6H, CH<sub>3</sub>N), 2.41 s (6H, CH<sub>3</sub>N), 5.33 s (1H, CH), 6.95–7.62 m (8H, H<sub>arom</sub>), 11.43 br.s (1H, NH), 11.48 br.s (1H, NH). <sup>13</sup>C NMR spectrum,  $\delta_{\rm C}$ , ppm: 40.5 and 40.6 (CH<sub>3</sub>N), 62.3 (C<sup>5</sup>), 68.2 (C<sup>1</sup>), 112.9–154.5 (C<sub>arom</sub>), 161.3 (C<sup>10</sup>), 161.4 (C<sup>6</sup>), 162.5 (C<sup>8</sup>), 164.5 (C<sup>4</sup>). Mass spectrum, *m/z* (*I*<sub>rel</sub>, %): 421 (11) [*M*]<sup>++</sup>, 420 (6), [*M* – 1]<sup>+</sup>, 259 (100), 162 (24.5). Found, %: C 62.52; H 5.34; N 16.47. C<sub>22</sub>H<sub>23</sub>N<sub>5</sub>O<sub>4</sub>. Calculated, %: C 62.70; H 5.50; N 16.62. *M* 421.45.

**1-(4-Methylphenyl)-4-phenyl-2-oxa-3,7,9-triazaspiro[4.5]dec-3-ene-6,8,10-trione (3j).** Yield 0.663 g (38%), colorless crystals, mp 255–260°C (decomp.). IR spectrum, v, cm<sup>-1</sup>: 3355 (NH), 1770, 1750 (C=O). <sup>1</sup>H NMR spectrum,  $\delta$ , ppm: 2.32 s (3H, CH<sub>3</sub>), 5.35 s (1H, CH), 7.05–7.55 m (9H, H<sub>arom</sub>), 11.42 br.s (1H, NH), 11.48 br.s (1H, NH). <sup>13</sup>C NMR spectrum,  $\delta_{C}$ , ppm: 21.6 (CH<sub>3</sub>), 62.4 (C<sup>5</sup>), 68.6 (C<sup>1</sup>), 125.6–137.3 (C<sub>arom</sub>), 161.4 (C<sup>6</sup>), 161.7 (C<sup>10</sup>), 162.5 (C<sup>8</sup>), 164.8 (C<sup>4</sup>). Mass spectrum, *m/z* (*I*<sub>rel</sub>, %): 349 (10) [*M*]<sup>+</sup>, 348 (5), [*M* – 1]<sup>+</sup>, 230 (100), 119 (18.5). Found, %: C 65.14; H 4.17; N 11.85. C<sub>19</sub>H<sub>15</sub>N<sub>3</sub>O<sub>4</sub>. Calculated, %: C 65.32; H 4.33; N 12.03. *M* 349.34.

**4-(4-Methoxyphenyl)-1-(4-methylphenyl)-2-oxa-3,7,9-triazaspiro[4.5]dec-3-ene-6,8,10-trione (3k).** Yield 0.663 g (35%), colorless crystals, mp 265–270°C (decomp.). IR spectrum, v, cm<sup>-1</sup>: 3355 (NH), 1770, 1750 (C=O). <sup>1</sup>H NMR spectrum, δ, ppm: 2.31 s (3H, CH<sub>3</sub>), 3.80 s (3H, CH<sub>3</sub>O), 5.31 s (1H, CH), 6.92–7.52 m (8H, H<sub>arom</sub>), 11.42 br.s (1H, NH), 11.48 br.s (1H, NH). <sup>13</sup>C NMR spectrum,  $\delta_{\rm C}$ , ppm: 21.5 (CH<sub>3</sub>), 55.4 (CH<sub>3</sub>O), 62.4 (C<sup>5</sup>), 68.2 (C<sup>1</sup>), 112.6–155.3 (C<sub>arom</sub>), 161.2 (C<sup>6</sup>), 161.5 (C<sup>10</sup>), 162.6 (C<sup>8</sup>), 164.6 (C<sup>4</sup>). Mass spectrum, *m/z* (*I*<sub>rel</sub>, %): 379 (10) [*M*]<sup>++</sup>, 378 (10), [*M* – 1]<sup>+</sup>, 230 (100), 149 (25.5). Found, %: C 63.13; H 4.37; N 10.91. C<sub>20</sub>H<sub>17</sub>N<sub>3</sub>O<sub>5</sub>. Calculated, %: C 63.22; H 4.52; N 11.08. *M* 379.37.

**4-(4-Dimethylaminophenyl)-1-(4-methylphenyl)-2-oxa-3,7,9-triazaspiro[4.5]dec-3-ene-6,8,10-trione (31).** Yield 0.725 g (37%), colorless crystals, mp 301– 307°C (decomp.). IR spectrum, v, cm<sup>-1</sup>: 3355 (NH), 1770, 1750 (C=O). <sup>1</sup>H NMR spectrum,  $\delta$ , ppm: 2.32 s (3H, CH<sub>3</sub>), 2.42 s (6H, CH<sub>3</sub>N), 5.32 s (1H, CH), 6.90– 7.55 m (8H, H<sub>arom</sub>), 11.42 br.s (1H, NH), 11.48 br.s (1H, NH). <sup>13</sup>C NMR spectrum,  $\delta_{C}$ , ppm: 21.4 (CH<sub>3</sub>), 40.5 (CH<sub>3</sub>N), 62.5 (C<sup>5</sup>), 68.3 (C<sup>1</sup>), 112.8–155.2 (C<sub>arom</sub>), 161.4 (C<sup>6</sup>), 161.6 (C<sup>10</sup>), 162.7 (C<sup>8</sup>), 164.6 (C<sup>4</sup>). Mass spectrum, m/z ( $I_{rel}$ , %): 392 (12) [M]<sup>+-</sup>, 391 (10), [M - 1]<sup>+</sup>, 230 (100), 162 (22.4). Found, %: C 64.09; H 4.95; N 14.11. C<sub>21</sub>H<sub>20</sub>N<sub>4</sub>O<sub>4</sub>. Calculated, %: C 64.28; H 5.14; N 14.28. M 392.41.

**3,4-Diphenyl-1,2,5-oxadiazole** *N***-oxide (4a).** Yield 0.747 g (52%), colorless crystals, mp 114°C [15].

**3,4-Bis(4-methoxyphenyl)-1,2,5-oxadiazole** *N***-oxide (4b).** Yield 0.969 g (54%), colorless crystals, mp 113°C [15].

**3,4-Bis(4-dimethylaminophenyl)-1,2,5-oxadiazole** *N***-oxide (4c).** Yield 1.065 g (55%), colorless crystals, mp 123°C [15].

### FUNDING

This study was performed under financial support by the Ministry of Science and Higher Education of the Russian Federation (project no. 4.9288.2017BCh).

## CONFLICT OF INTERESTS

The authors declare the absence of conflict of interests.

#### REFERENCES

- Baranski, A. and Kelarev, V.I., *Chem. Heterocycl. Compd.*, 1990, vol. 26, p. 371. doi 10.1007/ BF00497204
- Baranski, A. and Shvekhgeimer, G.A., Pol. J. Chem., 1982, vol. 56, p. 459.
- 3. Ladyzhnikova, T.D., Altukhov, K.V., and Solov'ev, N.A., *Zh. Org. Khim.*, 1986, vol. 22, p. 2618.
- 4. Tyrkov, A.G. and Suikhanova, B.G., *Russ. J. Org. Chem.*, 1999, vol. 35, p. 1299.
- Tyrkov, A.G., Russ. J. Org. Chem., 2002, vol. 38, p. 1218. doi 10.1023/A:1020934400960
- Grundmann, C. and Richter, R., J. Org. Chem., 1968, vol. 33, p. 476. doi 10.1021/jo01265a120
- Yurtaeva, E.A. and Tyrkov, A.G., Russ. J. Org. Chem., 2016, vol. 52, p. 289. doi.10.1134/s1070428016020214
- Shvekhgeimer, G.A., Baranski, A., and Grzegozek, M., Synthesis, 1976, no. 9, p. 611. doi 10.1055/s-1976-24140
- Granik, V.G., Osnovy meditsinskoi khimii (Fundamentals of Medicinal Chemistry), Moscow: Vuzovskaya Kniga, 2001, p. 248.
- Mashkovskii, M.D., Lekarstvennye sredstva (Medicines), Moscow: Novaya Volna, 2002, 14th ed., vol. 1, p. 432.

RUSSIAN JOURNAL OF ORGANIC CHEMISTRY Vol. 55 No. 7 2019

- Kirchner, J.G., *Thin-Layer Chromatography*, Perry, E.S., Ed., New York: Wiley, 1978, 2nd ed. Translated under the title *Tonkosloinaya khromatografiya*, Moscow: Mir, 1981, vol. 1, pp. 129, 228.
- Luzhnova, S.A., Tyrkov, A.G., Gabitova, N.M., and Yurtaeva, E.A., *Pharm. Chem. J.*, 2018, vol. 52, p. 506. doi 10.1007/s11094-018-1849-7
- Weygand, C., Organisch-chemische Experimentierkunst, Leipzig, Johann Ambrosius Barth, 1938. Translated under the title Metody eksperimenta v

*organicheskoi khimii*, Moscow: Inostrannaya Literatura, 1952, vol. 2, p. 288.

- Reaktsii i metody issledovaniya organicheskikh compoundi (Reactions and Methods of Investigation of Organic Compounds), Moscow: GNTIKhL, 1957, vol. 6, p. 39.
- 15. Khmel'nitskii, L.I., Novikov, S.S., and Godovikova, T.I., *Khimiya furoksanov (stroenie i sintez)* (Chemistry of Furoxans. Structure and Synthesis), Moscow: Nauka, 1981, p. 129.